Abbott Laboratories
ABT127.995USD
+2.535+2.02%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
222.57BCap. mercado
15.94P/E TTM
Más Datos de Abbott Laboratories Compañía
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
Información de Abbott Laboratories
Símbolo de cotizaciónABT
Nombre de la empresaAbbott Laboratories
Fecha de salida a bolsaApr 06, 2073
Director ejecutivoFord (Robert B)
Número de empleados114000
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 06
Dirección100 Abbott Park Road
CiudadABBOTT PARK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal60064-3500
Teléfono12246676100
Sitio Webhttps://www.abbott.com
Símbolo de cotizaciónABT
Fecha de salida a bolsaApr 06, 2073
Director ejecutivoFord (Robert B)
Ejecutivos de Abbott Laboratories
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-0.75%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Otro
4.53B
40.67%
Por regiónUSD
Nombre
Ganancia
Proporción
All other Countries
6.87B
61.62%
United States
4.28B
38.38%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Otro
4.53B
40.67%
Estadísticas de accionistas
Actualizado: lun., 17 de nov
Actualizado: lun., 17 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Otro
74.54%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.13%
State Street Investment Management (US)
4.50%
Capital International Investors
3.54%
Capital Research Global Investors
2.23%
Otro
74.54%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
47.15%
Investment Advisor/Hedge Fund
23.10%
Research Firm
3.49%
Pension Fund
2.34%
Bank and Trust
2.20%
Sovereign Wealth Fund
1.37%
Insurance Company
1.02%
Hedge Fund
0.49%
Individual Investor
0.48%
Otro
18.36%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
4606
1.42B
81.82%
+3.92M
2025Q3
4681
1.42B
81.87%
+8.53M
2025Q2
4668
1.41B
81.51%
+6.23M
2025Q1
4636
1.40B
80.10%
+7.18M
2024Q4
4554
1.38B
78.81%
+33.68M
2024Q3
4367
1.35B
78.83%
-5.95M
2024Q2
4376
1.35B
78.36%
+5.03M
2024Q1
4375
1.35B
77.56%
-1.86M
2023Q4
4400
1.34B
77.62%
+7.10M
2023Q3
4258
1.33B
78.26%
-4.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
172.03M
9.88%
+2.96M
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
88.52M
5.09%
+696.11K
+0.79%
Jun 30, 2025
State Street Investment Management (US)
78.35M
4.5%
+689.52K
+0.89%
Jun 30, 2025
Capital International Investors
60.14M
3.46%
-6.69M
-10.01%
Jun 30, 2025
Capital Research Global Investors
41.77M
2.4%
-8.97M
-17.68%
Jun 30, 2025
Geode Capital Management, L.L.C.
38.29M
2.2%
+1.39M
+3.77%
Jun 30, 2025
Wellington Management Company, LLP
25.05M
1.44%
-4.71M
-15.83%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
JP Morgan Asset Management
26.38M
1.52%
-2.42M
-8.39%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: mié., 5 de nov
Actualizado: mié., 5 de nov
Nombre
Proporción
iShares U.S. Medical Devices ETF
19.31%
Goldman Sachs Future Health Care Equity ETF
6.26%
SMI 3Fourteen Full-Cycle Trend ETF
5.01%
Invesco Pharmaceuticals ETF
4.99%
Health Care Select Sector SPDR Fund
4.62%
Proshares Ultra Health Care
4.61%
Tema Heart & Health ETF
4.5%
iShares U.S. Healthcare ETF
4.42%
AdvisorShares Focused Equity ETF
4.37%
Polen Capital Global Growth ETF
4.27%
Ver más
iShares U.S. Medical Devices ETF
Proporción19.31%
Goldman Sachs Future Health Care Equity ETF
Proporción6.26%
SMI 3Fourteen Full-Cycle Trend ETF
Proporción5.01%
Invesco Pharmaceuticals ETF
Proporción4.99%
Health Care Select Sector SPDR Fund
Proporción4.62%
Proshares Ultra Health Care
Proporción4.61%
Tema Heart & Health ETF
Proporción4.5%
iShares U.S. Healthcare ETF
Proporción4.42%
AdvisorShares Focused Equity ETF
Proporción4.37%
Polen Capital Global Growth ETF
Proporción4.27%
Dividendos
Un total de
16.46B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sep 19, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Nov 17, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 17, 2025
Oct 15, 2025
Jun 13, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 21, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Dec 13, 2024
ABT.NB Final Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Abbott Laboratories?
Los cinco principales accionistas de Abbott Laboratories son:
The Vanguard Group, Inc. posee 172.03M acciones, lo que representa el 9.88% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 88.52M acciones, lo que representa el 5.09% del total de acciones.
State Street Investment Management (US) posee 78.35M acciones, lo que representa el 4.50% del total de acciones.
Capital International Investors posee 60.14M acciones, lo que representa el 3.46% del total de acciones.
Capital Research Global Investors posee 41.77M acciones, lo que representa el 2.40% del total de acciones.
The Vanguard Group, Inc. posee 172.03M acciones, lo que representa el 9.88% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 88.52M acciones, lo que representa el 5.09% del total de acciones.
State Street Investment Management (US) posee 78.35M acciones, lo que representa el 4.50% del total de acciones.
Capital International Investors posee 60.14M acciones, lo que representa el 3.46% del total de acciones.
Capital Research Global Investors posee 41.77M acciones, lo que representa el 2.40% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Abbott Laboratories?
Los tres principales tipos de accionista de Abbott Laboratories son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Abbott Laboratories (ABT)?
A fecha de 2025Q4, 4606 instituciones poseen acciones de Abbott Laboratories, con un valor de mercado combinado de aproximadamente 1.42B, lo que representa el 81.82% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.05%.
¿Cuál es la mayor fuente de ganancias de Abbott Laboratories?
El FY2025Q2, el segmento empresarial Diabetes Care generó la ganancia más alta para Abbott Laboratories, ascendiendo a 1.98B y representando el 17.78% de la ganancia total.
